Alendronate present in Generic Fosamax demonstrates favored localization to sites of bone resorption, precisely under osteoclasts. The osteoclasts stick normally to the bone surface but are deprived of the tangled border suggestive of active resorption. Alendronate does not hinder osteoclast recruitment or attachment, but inhibits osteoclast activity. Though merged in bone matrix, alendronate is not pharmacologically active and hence must be continuously taken to suppress osteoclasts on newly formed resorption surfaces. Alendronate treatment decreases bone turnover (i.e., the number of sites at which bone is remodeled). Hence, bone formation outdoes bone resorption at these remodeling sites, leading to advanced gain in bone mass.